Navigation Links
Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
Date:5/8/2009

ation that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. For more information on Daiichi Sankyo, Inc., please visit

www.dsi.com.

(1) American Heart Association. An Overview of the Kidney in Cardiovascular Disease. Available at: http://www.americanheart.org/presenter.jhtml?identifier=681. Accessed on April 16, 2009.

(2) World Health Organization. Diabetes Program: Country and Regional Data. Found at: http://www.who.int/diabetes/facts/world_figures/en/. Accessed April 3, 2009.

(3) Center For Disease Control and Prevention, National Diabetes Fact Sheet, 2007. Found at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed September 3, 2008.

(4) Ibid.

(5) National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC). Kidney Dise
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
3. New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Regurgitation
4. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
5. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
6. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
7. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
8. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
10. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
11. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Calif. , July 29, 2015 Sangamo ... the company will release its second quarter 2015 financial ... 2015. The press release will be followed by a ... open to the public via telephone and webcast. During ... financial results and discuss other business matters. ...
(Date:7/29/2015)... 29, 2015 Alvarado Hospital unveiled its ... Alvarado Spine & Joint Institute. The institute is ... on spinal surgery and joint replacement. The Spine ... a patient experience-focused approach. For example, patients are ... in, rather than patient gowns. ...
(Date:7/29/2015)... July 29, 2015   Turing Pharmaceuticals AG ... joined the company as its first Chief Communication Officer. ... have overall responsibility for internal and external communications and ... He will report directly to Founder and Chairman, ... Leadership Team. "We are excited to have ...
Breaking Medicine Technology:Sangamo BioSciences Announces Second Quarter 2015 Conference Call and Webcast 2The Alvarado Spine & Joint Institute Opens July 30 in San Diego 2Turing Pharmaceuticals Names Craig Rothenberg Chief Communication Officer 2Turing Pharmaceuticals Names Craig Rothenberg Chief Communication Officer 3
... 8 Nektar,Therapeutics (Nasdaq: NKTR ) today ... program to evaluate NKTR-102 (PEG-irinotecan) as a,potential treatment ... using the company,s innovative small molecule,PEGylation technology platform., ... for NKTR-102 in colorectal cancer is,a major achievement ...
... Trial Data and Emerging Clinical Practice Experience Support ... HYLENEX Efficacy ... Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and ... publication of the INFUSE-LR clinical trial results in the Journal,of ...
Cached Medicine Technology:Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 2Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 3Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 2Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 3Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 5
(Date:7/29/2015)... ... 2015 , ... Abt Associates has named Selena Ramkeesoon, a ... In her position, Ramkeesoon will help build and expand work in communications, and ... to a decade at ICF International, most recently as a vice president. During ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to the The Media ... and are exposed to advertisements, for medicinal use are more likely to abuse the ... the use of marijuana is considered beneficial are more apt to use the substance, ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may ... MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with ...
(Date:7/29/2015)... ... 29, 2015 , ... The NCCA re-accredited the Commission for ... 30, 2019, during its recent meeting. , The Commission received renewal of NCCA ... with the NCCA’s Standards for the Accreditation of Certification Programs. NCCA is ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... Michigan, changed its name in July to Kalamazoo Strength & Conditioning. , The ... , and “reflects the evolution of our training center over the past three ...
Breaking Medicine News(10 mins):Health News:Selena Ramkeesoon Joins Abt Associates as Vice President for Strategic Communications 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4
... study has shown that those people who eat breakfast regularly ... The researchers found from the Children’s Hospital in Boston that ... per cent lower among people who ate breakfast compared to ... Insulin resistance syndrome is a disorder that includes// obesity, high ...
... reported by researchers in the Journal of Hypertension ... morbidity and improve their atherosclerotic risk profile by ... indicated that serum lipoprotein(a), a powerful predictor of ... The researchers studied 402 patients with untreated essential ...
... now much easier than earlier and according to James ... many people, both men and women are seeing plastic ... past, when patients would wait until they were 50 ... signs of aging. He also added that non-surgical treatments ...
... Drug Administration's(FDA) new effort to re-examine very old ... required proof that drugs worked well, has landed ... trouble. Until now FDA stressed that the expectorant, ... crackdown lead to the FDA formally approving sale ...
... Institute, led by Glenn Dranoff, MD,have reported in the ... vaccines made from patients' own tumors are safe and ... for deadly cancers. Researchers claim that the tumors grow ... immune system attacks -- ignore them. In the new ...
... for Preventing and Reversing Atherosclerosis in Houston, Texas, ... that intense lifestyle changes plus pharmacologic lipid treatment ... a greater extent than usual-care cholesterol lowering drugs. ... by performing myocardial perfusion imaging at baseline and ...
Cached Medicine News:Health News:New lung cancer vaccine on the anvil 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: